Top in endocrinology: Weight loss drug; initiating insulin pump therapy in primary care
Click Here to Manage Email Alerts
Topline data from the SURMOUNT-1 trial showed that once-weekly treatment with tirzepatide reduced weight among adults with overweight or obesity.
According to a press release from the manufacturer, the drug met both primary endpoints for mean percentage change in body weight from baseline and percentage of participants with a 5% reduction in body weight compared with placebo. It was the top story in endocrinology last week.
Another top story featured a conversation between Susan Weiner, MS, RDN, CDCES, FADCES, Endocrine Today Diabetes in Real Life column editor, and Michael Heile, MD, FAAFP, BC-ADM, a primary care physician and person living with type 1 diabetes, about the benefits of insulin pump therapy for patients with type 2 diabetes and initiating it in the primary care setting.
Read these and more top stories in endocrinology below:
SURMOUNT-1: Adults achieve weight loss of 16% or more at 72 weeks with tirzepatide
Adults with overweight or obesity taking the once-weekly GIP/GLP-1 receptor agonist tirzepatide (Eli Lilly) achieved a mean weight loss of at least 16% at 72 weeks, according to topline results from the SURMOUNT-1 clinical trial. Read more.
Insulin pump therapy can be initiated in primary care
Susan Weiner, MS, RDN, CDCES, FADCES, talks with Michael Heile, MD, FAAFP, BC-ADM, a primary care physician and person living with type 1 diabetes, about the benefits of insulin pump therapy for people with type 2 diabetes who use insulin. Read more.
Type 2 diabetes increases risk for tooth loss
Data from cross-sectional studies have found an association between type 2 diabetes and an increased risk for tooth loss. The findings were published in BMC Endocrine Disorders. Read more.
Obesity disparities greater among children attending racially segregated schools
Racial and ethnic disparities in obesity prevalence are greater among children attending more racially segregated schools compared with those attending integrated schools, according to study findings published in Obesity. Read more.
Diabetes overtreatment common in nursing homes, with little medication deintensification
Type 2 diabetes overtreatment among nursing home residents is common, with few residents having their medication regimens appropriately deintensified, according to results published in the Journal of the American Geriatric Society. Read more.